Business Update Neutral

2026-11-06 17:24

Current scenario - Q2 FY27 total income stood at ₹457.2 Cr vs ₹516.1 Cr YoY. - EBITDA for the quarter was ₹104.6 Cr (22.9% margin) compared to ₹156.9 Cr (30.4% margin) YoY. - Profit after tax (PAT) stood at ₹51.1 Cr compared to ₹96.5 Cr YoY. - First-half performance was impacted by input cost inflation, geopolitical turbulence, and supply chain volatility. Changes in trends - Revenues exhibited sequential moderation primarily due to the lumpy nature of commercial shipments in the CMS business. - Working capital days increased to 104 days from 84 days in the previous quarter. - Gross margins remained stable at 59.4% compared to 60.1% in Q2 FY26. Management Guidance & Outlook - Management remains confident about growth expectations remaining intact for the remainder of FY27 and the following financial year. - The long-term demand for complex small molecules and peptide APIs continues to be robust. Capex - H1 FY27 capex outflow stood at ₹261 Cr, with free cash flows at ₹99 Cr and net debt at negative ₹208 Cr. - The new peptide block at Unit 1 was successfully commissioned, and the process R&D center at Genome Valley is expected to be fully operational by early next year. - Approximately 134 acres of land was acquired at Kakinada to support long-term expansion. Growth Drivers - Increasing contributions from custom manufacturing solutions (CMS) and commercial NCEs. - Portfolio expansion supported by DMF filings for Fezolinetant and Ivacaftor. - Deepening customer relationships with big pharma and scaling up capabilities in peptide manufacturing.

Business Update Neutral

2026-11-06 10:58

Concall Schedule Concall Date: November 17, 2026 Concall Time: Not specified Event: JM Financial Annual India Conference - India Xchange 2026 in Mumbai

Routine Neutral

2026-11-05 12:57

- Neuland Laboratories Limited informed the exchanges about the change in the corporate office address of its Registrar and Share Transfer Agent (RTA), KFIN Technologies Limited. - The new corporate office address will be effective from December 1, 2026, located at Kokapet, Hyderabad. - The registered office of the RTA remains unchanged.

Routine Neutral

2026-11-03 19:58

- Neuland Laboratories Limited has submitted the audio recording link for the earnings call conducted on November 3, 2026. - The call pertains to the financial results for the quarter and half year ended September 30, 2026. - The recording is made available on the company's official website as per SEBI regulations.

Business Update Neutral

2026-11-03 16:27

- Q2FY27 Total Income fell 11.4% YoY to ₹457.2 Cr; PAT decreased 47% YoY to ₹51.1 Cr. - EBITDA stood at ₹104.6 Cr with margin at 22.9% (-754 bps YoY). - H1FY27 Total Income grew 35.6% YoY to ₹1,107.2 Cr; PAT up 80.2% to ₹198.5 Cr. - Management reaffirmed growth outlook for FY27.

Routine Neutral

2026-11-03 16:23

New Filing detected. See link for details.

Financials Neutral

2026-11-03 16:06

Q2 FY27 Consolidated Revenue ₹449.66Cr vs ₹514.27Cr (▼12.6% YoY) EBITDA ₹97.56Cr vs ₹155.55Cr (▼37.3% YoY) PAT ₹51.63Cr vs ₹96.85Cr (▼46.7% YoY) EBITDA Margin 21.7% vs 30.2% (▼854bps) - Board approved capex of ₹47.1 Cr for land acquisition (Ac.6-00 Gts) at Domadugu Village, Telangana for future capacity expansion.

Financials Neutral

2026-11-03 15:51

Q2 FY27 Consolidated Revenue ₹450Cr vs ₹514Cr (▼13% YoY) EBITDA ₹98Cr vs ₹156Cr (▼37% YoY) PAT ₹52Cr vs ₹97Cr (▼47% YoY) EBITDA Margin 21.7% vs 30.2% (▼854bps) Board approved capital expenditure of ₹47.1 Cr for land acquisition in Telangana for future capacity expansion.

Business Update Neutral

2026-10-28 12:59

Concall Schedule Concall Date: November 03, 2026 Concall Time: 17:30 Hrs (IST)

Business Update Positive

2026-10-14 21:45

- US FDA issued an Establishment Inspection Report (EIR) for the inspection conducted at Unit 3 manufacturing facility from August 10, 2026 to August 14, 2026. - The US FDA has officially concluded that the inspection is closed.

Routine Neutral

2026-09-25 15:23

- Trading window for dealing in company equity shares will remain closed from October 1, 2026. - Closure will remain effective until 48 hours after declaration of financial results for Q2/half-year ended September 30, 2026. - Date of the Board Meeting will be intimated in due course.

Business Update Neutral

2026-09-16 16:14

- Neuland Laboratories Ltd management will participate in the Goldman Sachs Global Healthcare CDMO Day event. - Date: September 23-25, 2026. - Location: Singapore. - Meeting Type: Group meet / One-on-One meet.

Business Update Positive

2026-09-15 10:29

- Neuland Laboratories has operationalized its first commercial peptide manufacturing module, part of a four-module expansion. - This $30M investment provides 7000L reactor capacity, enhancing capabilities for complex peptide APIs and meeting rising customer demand. - Further capacity expansion is underway.

Business Update Neutral

2026-09-09 18:10

- Schedule of Analyst / Institutional Investor Meetings - Date: September 15, 2026 - Emkay Global Investors Meeting (Hyderabad) - Date: September 17, 2026 - ICICI Securities Healthcare Day (Hyderabad)

Business Update Positive

2026-09-07 17:26

- Board approved capital expenditure of ₹126 Cr. - For purchasing ~134 acres of land in Kakinada, Andhra Pradesh, for future expansion. - Company has right to acquire an additional ~66 acres, totaling ~200 acres. - Financed through internal accruals.

Business Update Positive

2026-08-25 20:41

- Crisil Ratings reaffirmed the Company's credit ratings. - Long Term Rating: CRISIL A+/Positive, with outlook revised to 'Positive'. - Short Term Rating: CRISIL A1, reaffirmed.

Business Update Negative

2026-08-14 18:56

CRITICAL RED FLAG DETECTED

- US FDA inspected Neuland Laboratories' Unit 3 facility from August 10-14, 2026. - A Form 483 was issued with one observation related to procedural improvements in water and environmental monitoring. - The company will submit its response to the FDA.

Business Update Positive

2026-08-10 18:59

- Neuland Laboratories reported strong Q1FY27 performance, with Total Income at INR 650.1 crores compared to INR 300.6 crores in Q1FY26 (▲116.3% YoY). - Profit After Tax (PAT) significantly increased to INR 147.4 crores from INR 13.7 crores in Q1FY26 (▲976.0% YoY), with EBITDA margin at 35.5%. - Management expects revenue growth of approximately 20% for FY27 and FY28, with FY27 anticipated as a year of overall growth. - Long-term EBITDA margin expectation is "25% plus," with current expectations for higher EBITDA. - A new peptide manufacturing plant is scheduled for commissioning next month, already having multiple projects lined up. - A strategic collaboration with Gland Pharma has been established to develop a differentiated platform in sterile APIs, seen as a long-term partnership. - The company is making significant investments in R&D, peptide, and sterile API capabilities, with future capital expenditure expected to be higher and focused on newer, more complex modalities. - Development revenue is projected to increase in FY27, with more molecules expected to contribute to commercial revenue from FY28 onwards.

Business Update Neutral

2026-08-07 13:45

- Analyst/Institutional Investor Meeting Scheduled - Meeting Date: August 12, 2026 - Event: Emkay Confluence 2026 - Location: Mumbai - Nature of Meeting: Group meet / One-on-One meet

Business Update Neutral

2026-08-05 22:23

- Audio recording of the Earnings call conducted on August 5, 2026, for the quarter ended June 30, 2026, is now available. - Weblink for access: https://www.neulandlabs.com/en/investors/investor-meetings/investor-call-recordings.

Financials Positive

2026-08-05 16:40

- Consolidated Revenue ₹64,157.71 lakhs vs ₹29,275.27 lakhs (▲119.15% YoY) - EBITDA ₹22,289.04 lakhs vs ₹3,448.89 lakhs (▲546.12% YoY) - PAT ₹14,767.31 lakhs vs ₹1,390.00 lakhs (▲962.39% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores in favour of Gland Pharma Limited for a Loan Licence Agreement to establish dedicated manufacturing capacity. - Approved enhancement of manufacturing capacity at Unit 1 by 18 KL for ₹39.8 crores (incl GST), funded by internal accruals, to meet growing customer demand. - Announced a strategic CDMO partnership with Gland Pharma for sterile API manufacturing, involving a new cGMP state-of-the-art sterile suite to add approximately 1400 kg of annual capacity.

Financials Positive

2026-08-05 16:33

- Consolidated Revenue ₹641.58Cr vs ₹292.75Cr (▲119.14% YoY) - EBITDA ₹222.89Cr vs ₹34.49Cr (▲546.28% YoY) - PAT ₹147.67Cr vs ₹13.90Cr (▲962.37% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores for a Loan Licence Agreement with Gland Pharma Limited to establish dedicated manufacturing capacity. - Approved enhancement of manufacturing capacity at Unit 1 by 18 KL with an investment of ₹39.8 crores, to be funded through internal accruals. - Announced a long-term strategic CDMO partnership with Gland Pharma for sterile API manufacturing, including a new dedicated sterile suite with ~1400 kg annual capacity.

Financials Positive

2026-08-05 16:18

- Consolidated Total Income ₹650.1 Cr vs ₹300.6 Cr (▲116.3% YoY) - EBITDA ₹231.1 Cr vs ₹42.1 Cr (▲448.2% YoY) - PAT ₹147.4 Cr vs ₹13.7 Cr (▲975.0% YoY) - EBITDA Margin 35.5% vs 14.0% (▲2150bps)

Financials Positive

2026-08-05 16:05

- Consolidated Revenue ₹641.58Cr vs ₹292.75Cr (▲119.16% YoY) - EBITDA ₹222.89Cr vs ₹34.49Cr (▲546.25% YoY) - PAT ₹147.67Cr vs ₹13.90Cr (▲962.37% YoY) - EBITDA Margin 34.74% vs 11.78% (▲2296bps) - Board approved a Corporate Guarantee of ₹40 crores for a Loan Licence Agreement with Gland Pharma Limited to establish dedicated manufacturing capacity. - Approved an 18 KL manufacturing capacity addition at Unit 1, costing ₹39.8 crores, to be completed in 6-7 months via internal accruals. - Announced a strategic CDMO partnership with Gland Pharma for sterile API manufacturing, including Gland Pharma establishing a dedicated sterile manufacturing suite with approx. 1400 kg annual capacity for Neuland.

Governance Positive

2026-08-04 17:39

- The 42nd Annual General Meeting (AGM) of Neuland Laboratories Limited was held on August 4, 2026, where all resolutions were passed with requisite majority. - Shareholders approved the Audited Financial Statements for the financial year ended March 31, 2026. - A final dividend of Rs. 34.00/- (340%) per equity share for FY2025-26 was declared. - Resolutions for the re-appointment of Dr. Davuluri Rama Mohan Rao and appointment of Dr. Mauricio Futran as Non-Executive Non-Independent Director were also passed.

Business Update Positive

2026-07-31 22:12

- Neuland Laboratories commenced commercial production of additional capacities at its Unit 1 (Bonthapally Village) and Unit 3 (Gaddapotharam Village) in Sangareddy District, Telangana, as part of its expansion plans.

Business Update Neutral

2026-07-28 11:53

- Concall Schedule for Q1 FY27 Earnings Conference Call - Concall Date: August 05, 2026 - Concall Time: 17:30 Hrs (IST)

Business Update Neutral

2026-07-13 17:39

- India Ratings and Research affirmed the credit rating for Neuland Laboratories Limited's bank loan facilities. - The rating remains IND A+/ Positive/ IND A1.

Routine Neutral

2026-07-09 20:26

New Filing detected. See link for details.

Routine Neutral

2026-07-09 19:42

New Filing detected. See link for details.

Governance Positive

2026-07-09 19:10

- Notice for the 42nd Annual General Meeting on August 4, 2026, at 10:00 a.m. via VC/OAVM. - Agenda includes adopting FY2025-26 financial statements and declaring a final dividend of ₹34/- per equity share. - Also covers re-appointment of Dr. D.R.M. Rao and appointment of Dr. M. Futran as Non-Executive Non-Independent Director.

Governance Neutral

2026-06-25 17:43

- Trading window for equity shares will close from July 1, 2026, until 48 hours after Q1 FY27 financial results declaration (quarter ended June 30, 2026). - The date of the Board Meeting for Q1 FY27 results will be intimated in due course.

Business Update Neutral

2026-06-05 09:59

- Analyst/Institutional Investor Meeting Schedule - Meeting Date: June 11, 2026 - Event: Goldman Sachs Non-deal roadshow (NDR) - Location: Hyderabad - Nature of meeting: Group meet / One-on-One meet

Business Update Neutral

2026-06-03 15:01

- Concall Schedule - Concall Date: June 8 & 9, 2026 - Event: Nuvama India Conference 2026 (UK Edition) - Location: London, United Kingdom - Meeting Type: Group meet / One-on-One meet

Business Update Neutral

2026-05-31 19:15

Neuland Laboratories Limited's management will participate in a group/one-on-one meeting with analysts and institutional investors from BOFA Healthcare Tour on June 5, 2026, in Hyderabad. This filing serves as an intimation of the scheduled investor interaction.

Business Update Neutral

2026-05-22 16:36

Neuland Laboratories Limited announced that its management will participate in the 360 ONE Capital(B&K) 16th Annual Investor Conference - TRINITY INDIA 2026 in Mumbai on May 28, 2026. The meeting will include group and one-on-one sessions with analysts and institutional investors.

Business Update Positive

2026-05-16 16:14

Management guided for an aspirational 18-20% CAGR over a 5-year period, expressing confidence in long-term growth driven by existing and new commercial molecules, particularly the significant $5-6 billion market opportunity in peptides. The company incurred a Capex outflow of INR397.1 crores in FY26 for large-scale peptide commercial facilities and a new R&D center, with the peptide facility on track to be operational by July. While FY26 free cash flow was negative due to investments and increased working capital (expected to normalize in FY27), the balance sheet remains strong with negative net debt. Management acknowledges quarterly business lumpiness and supply chain volatility but focuses on execution discipline and strategic capital allocation for future expansion.

Business Update Neutral

2026-05-12 19:49

Neuland Laboratories Limited announced the availability of the audio recording of its earnings call, which was conducted on May 12, 2026. The call discussed the financial results for the quarter and year ended March 31, 2026. A weblink to access the recording has been provided.

Financials Positive

2026-05-12 19:26

For the year ended March 31, 2026, Consolidated Revenue from operations increased to ₹2023Cr vs ₹1477Cr (▲37% YoY), EBITDA to ₹575Cr vs ₹410Cr (▲40% YoY), and PAT to ₹364Cr vs ₹260Cr (▲40% YoY). EBITDA Margin expanded to 28.4% vs 27.7% (▲65bps). The company recommended a final dividend of Rs. 34/- per equity share for FY2025-26 and approved a capacity enhancement of 120.5 KL at Unit 1 with a ₹143.4 crore investment, to be completed in 12-18 months.

Financials Positive

2026-05-12 19:17

Consolidated Revenue ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2316bps).

Financials Positive

2026-05-12 18:51

Neuland Laboratories reported strong Q4FY26 results: Total Income ₹788.7 Cr vs ₹335.8 Cr (▲134.9% YoY), EBITDA ₹319.4 Cr vs ₹58.2 Cr (▲448.6% YoY), PAT ₹212.5 Cr vs ₹27.7 Cr (▲666.3% YoY). EBITDA Margin expanded significantly from 17.3% to 40.5% (▲2316bps). Management expressed satisfaction with ending FY26 on a strong note, in line with expectations, and noted good business visibility.

Financials Positive

2026-05-12 18:50

Neuland Laboratories Limited's Board approved the Audited Annual Financial Results for FY 2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. The company plans to enhance capacity at Unit 1 by 120.5 KL, investing ₹143.4 crores over 12-18 months to meet growing demand. Dr. Mauricio Futran was appointed as an Additional Director.

Financials Positive

2026-05-12 18:50

The Board approved the Audited Financial Results for the year ended March 31, 2026, and recommended a final dividend of Rs. 34/- (340%) per equity share for FY 2025-26. Dr. Mauricio Futran was appointed as an Additional Director. The 42nd Annual General Meeting (AGM) will be held on August 4, 2026, with July 24, 2026, as the record date for the dividend. The company also approved a capacity enhancement of 120.5 KL at Unit 1, requiring an investment of ₹143.4 crores, to be completed within 12-18 months.

Financials Positive

2026-05-12 18:49

Neuland Laboratories Limited's Board approved Audited Annual Financial Results for FY2025-26 and recommended a final dividend of Rs. 34/- per equity share. To meet growing demand, the company announced a capacity enhancement of 120.5 KL at Unit 1 with an investment of Rs. 143.4 crores, funded by internal accruals and borrowings. Dr. Mauricio Futran was also appointed as an Additional Director.

Business Update Positive

2026-05-12 18:48

Neuland Laboratories' Board approved annual financial results for FY2025-26 and recommended a final dividend of Rs. 34/- (340%) per equity share. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive Non-Independent) effective May 12, 2026. The company announced a capacity expansion at Unit 1 by 120.5 KL, investing ₹143.4 crores, to be completed in 12-18 months to meet growing demand. The 42nd AGM is scheduled for August 4, 2026, with July 24, 2026, as the record date.

Financials Positive

2026-05-12 16:49

Consolidated Total Income ₹788.7Cr vs ₹335.8Cr (▲134.9% YoY), EBITDA ₹319.4Cr vs ₹58.2Cr (▲448.6% YoY), PAT ₹212.5Cr vs ₹27.7Cr (▲666.3% YoY). EBITDA Margin 40.5% vs 17.3% (▲2320bps). Management highlighted strong performance in line with expectations, good business visibility, and investments in Peptide Manufacturing and a new R&D Centre for future growth.

Financials Positive

2026-05-12 16:27

Consolidated Revenue for the quarter ended March 31, 2026, was ₹788.71Cr vs ₹335.82Cr (▲134.89% YoY), EBITDA ₹307.33Cr vs ₹51.07Cr (▲501.74% YoY), PAT ₹212.67Cr vs ₹27.81Cr (▲664.12% YoY). EBITDA Margin expanded to 38.97% vs 15.21% (▲2376bps). The Board also recommended a final dividend of ₹34 per share for FY26 and approved a capacity expansion project of 120.5 KL at Unit 1 with an investment of ₹143.4 crores.

Financials Positive

2026-05-12 16:25

Consolidated annual results for the year ended March 31, 2026: Revenue from operations ₹2,022.99 Cr vs ₹1,476.84 Cr (▲37.0% YoY), EBITDA ₹574.50 Cr vs ₹399.66 Cr (▲43.7% YoY), PAT ₹364.00 Cr vs ₹260.11 Cr (▲39.9% YoY). EBITDA Margin 28.39% vs 27.06% (▲133bps). The board recommended a final dividend of ₹34/- per equity share for FY26 and approved a 120.5 KL capacity expansion at Unit 1 with a ₹143.4 Cr investment to meet growing demand.

NEULANDLAB

Neuland Laboratories Limited

Price Chart

Filing History

Unlock Full History